Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), routinely used to treat advanced non-small-cell lung cancer (NSCLC) patients with activated EGFR mutations, are associated with excellent response and improved performance status. Recently, pro-inflammatory cytoki...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Umekawa, Kanako, Kimura, Tatsuo, Kudoh, Shinzoh, Suzumura, Tomohiro, Oka, Takako, Nagata, Misato, Mitsuoka, Shigeki, Matsuura, Kuniomi, Nakai, Toshiyuki, Yoshimura, Naruo, Kira, Yukimi, Hirata, Kazuto
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2013
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3637543/
https://ncbi.nlm.nih.gov/pubmed/23566546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-6-139
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller